Moderna Capitalizes On Its Headstart In COVID-19 Vaccines

Leaked List Shows Premium Price Secured With EU

The US biotech has booked orders of nearly 500 million doses for its COVID-19 vaccine, and a leaked price list from Europe shows it has secured a premium price ahead of all its rivals, including Pfizer/BioNTech.

Moderna looks set to earn over $9bn from its COVID-19 vaccine next year.

More from COVID-19

More from Scrip